Pavlo Kot

Cullinan Therapeutics reveals Q3 2026 earnings and outlines upcoming pipeline milestones

Cullinan Therapeutics reveals Q3 2026 earnings and outlines upcoming pipeline milestones
Cullinan Q3 2026 results and update

Cullinan Therapeutics released its corporate update and reported financial results for the third quarter of 2026. The company also provided an overview of upcoming milestones across its T cell engager pipeline.

The announcement signals the firm's continued efforts to advance its immuno-oncology programs. Full details are available through the official company update.

Cullinan Therapeutics recently shared new clinical data from its Genrix Phase 1b 2a study of velinotamig for SLE at the ACR26 conference, according to a company update (link). Earlier, the firm received FDA and TGA clearance to initiate a global Phase 1 2 study of velinotamig in autoimmune blood disorders (link). These developments reflect the company’s active clinical pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.